The case for introducing pre-registered confirmatory pharmacological pre-clinical studies

Area of Science:

• Neuroscience
• Translational Medicine
• Research Methodology

Background:

• Pre-clinical studies in traumatic brain injury (TBI) often differ significantly from phase III clinical trials.
• These design discrepancies may contribute to the challenges in translating experimental therapies into approved treatments.
• Existing research evaluation methods may not adequately address potential biases in pre-clinical research.

Purpose of the Study:

• To evaluate the design characteristics of pre-clinical studies for traumatic brain injury.
• To identify potential reasons for the difficulties in translating pre-clinical findings to clinical success.
• To propose improvements in the design and evaluation of pre-clinical research.

Main Methods:

• Comparative analysis of pre-clinical study designs versus phase III clinical trial protocols in TBI research.
• Network analysis to assess researcher interrelationships and potential impact on study outcomes.
• Literature review and critical appraisal of existing pre-clinical research methodologies.

Main Results:

• Substantial design differences were identified between pre-clinical TBI studies and phase III clinical trials.
• Network analysis indicated instances of high interconnectedness among researchers conducting pre-clinical studies for specific treatments.
• These factors may contribute to the high failure rate of drug translation from pre-clinical to clinical stages.

Conclusions:

• The heterogeneity in pre-clinical study design poses a significant barrier to effective drug development in TBI.
• Addressing researcher interrelationships and implementing more rigorous study designs are crucial.
• A clear distinction between exploratory and confirmatory pre-clinical studies is recommended to improve research rigor and translation potential.